BeOne Medicines (BEIGF) Common Equity (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Common Equity data on file, last reported at $4.8 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $4.8 billion, up 36.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 36.03% YoY), and the FY2025 annual result was $4.4 billion, up 30.88% from the prior year.
• Common Equity advanced to $4.8 billion in Q1 2026 per BEIGF's latest filing, from $4.4 billion in the prior quarter.
• Over five years, Common Equity peaked at $5.8 billion in Q1 2022 and troughed at $3.3 billion in Q4 2024.
• A 5-year average of $4.1 billion and a median of $3.8 billion in 2023 frame the typical range for Common Equity.
• On a YoY basis, Common Equity climbed as much as 44.22% in 2022 and fell as far as 28.52% in 2022.
• A 5-year view of Common Equity shows it stood at $4.4 billion in 2022, then fell by 19.3% to $3.5 billion in 2023, then dropped by 5.8% to $3.3 billion in 2024, then soared by 30.88% to $4.4 billion in 2025, then advanced by 9.15% to $4.8 billion in 2026.
• Business Quant data shows BEIGF's Common Equity at $4.8 billion in Q1 2026, $4.4 billion in Q4 2025, and $4.1 billion in Q3 2025.